Piper Sandler reiterates Overweight rating on Medtronic stock as Affera gains traction
PositiveFinancial Markets

Piper Sandler has reaffirmed its Overweight rating on Medtronic's stock, highlighting the growing success of Affera, a company that Medtronic recently acquired. This endorsement is significant as it reflects confidence in Medtronic's strategic direction and potential for growth in the medical technology sector. Investors may find this news encouraging, as it suggests that Medtronic is on a positive trajectory, particularly with the integration of Affera's innovative solutions.
— Curated by the World Pulse Now AI Editorial System








